EE20/DRSP (YAZ, BAY86-5300)

DRUG4 trials

Sponsors

Bayer

Conditions

AcneContraceptionContraceptives, OralOral ContraceptiveOvulation InhibitionPremenstrual Syndrome

Phase 3

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

CompletedNCT00567164

BayerContraception, Contraceptives, Oral, Ovulation Inhibition

Start: 2007-10-31End: 2009-11-30Updated: 2014-03-12

Comparative Trial in Hormone Withdrawal Associated Symptoms

CompletedNCT01076582

BayerOral Contraceptive

Start: 2010-04-30End: 2011-10-31Updated: 2014-10-28

Phase 4

YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China

CompletedNCT02710708

BayerContraception

Start: 2016-05-27End: 2018-07-03Updated: 2019-06-28

Unknown Phase

Regulatory Post Marketing Surveillance Study on YAZ

CompletedNCT00998257

BayerAcne, Contraception, Premenstrual Syndrome

Start: 2009-07-31End: 2011-11-30Updated: 2015-01-21

Related Papers

Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study.

2020-01-164 citations

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen).

2015-05-185 citations